Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Rhumbline Advisers

Rhumbline Advisers reduced its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 267,933 shares of the biotechnology company’s stock after selling 2,939 shares during the period. Rhumbline Advisers owned 0.28% of Sarepta Therapeutics worth $32,578,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in SRPT. Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after buying an additional 665,087 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Sarepta Therapeutics during the 3rd quarter worth $79,425,000. Janus Henderson Group PLC boosted its position in shares of Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares during the last quarter. Soros Fund Management LLC purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $25,800,000. Finally, Swedbank AB acquired a new stake in Sarepta Therapeutics during the fourth quarter worth about $16,706,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Down 2.4 %

Shares of NASDAQ:SRPT opened at $105.35 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a fifty-two week low of $101.15 and a fifty-two week high of $173.25. The stock has a market cap of $10.06 billion, a price-to-earnings ratio of 84.28 and a beta of 0.75. The firm’s 50 day moving average price is $118.57 and its 200 day moving average price is $124.07.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SRPT shares. HC Wainwright reissued a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 13th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Evercore ISI lowered their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $176.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.